Why is the federal investment in the diaMentis project so important?, says Normand Tremblay, President and CEO of the company.
This allows us to accelerate the deployment of the study which is underway. […] It is the only clinical study underway in the development of a diagnostic aid tool.
it is a retinal exam and we are able to say, “We are in the universe of schizophrenia, type 1 bipolarity, type 2 bipolarity or in the universe of major depression”, continues the president of the company.
The technology initially comes from research work at Laval University.
In mental health, there are clinical symptoms and there is no supporting biological tool., remarks the president.
However, he recalls that
20% of the population of industrialized countries, or 450 million people according to theWHO, is affected by mental illness, including 1 in 5 Canadians, but also that the most important cause of lost productivity in the country remains mental health.
About twenty people are already part of the team and the company, which has developed 5 patents, plans to create 10 jobs in the short term.
By investing in diaMentis, we are investing in innovation, new technologies and the creation of good jobs here in Quebec., said the Leader of the Government in the House of Commons and Member of Parliament for Honoré-Mercier, Pablo Rodriguez.
For his part, the deputy for Louis-Hébert Joël Lightbound judges that the company could
completely revolutionize the way we diagnose different mental health disorders.
Federal government funds were granted under the Regional Economic Growth through Innovation program of Canada Economic Development for Quebec Regions (CED). A program aimed at entrepreneurs and regional economic players.
To listen :
Normand Tremblay, President and CEO of diaMentis, interviewed on the show It’s even better in the afternoon